Vaccines, inspiring innovation in health.
Identifieur interne : 000894 ( PubMed/Curation ); précédent : 000893; suivant : 000895Vaccines, inspiring innovation in health.
Auteurs : Sonia Pagliusi [Suisse] ; Maureen Dennehy [Suisse] ; Hun Kim [Corée du Sud]Source :
- Vaccine [ 1873-2518 ] ; 2018.
Descripteurs français
- KwdFr :
- Coopération internationale, Humains, Infection par le virus Zika (), Maladies négligées (), Organisation mondiale de la santé, Pays en voie de développement, Poliomyélite (), Programmes de vaccination (), Programmes de vaccination (économie), Santé mondiale, Santé publique (législation et jurisprudence), Santé publique (économie), Secteur privé, Vaccins, Épidémies (), Éradication de maladie.
- MESH :
- législation et jurisprudence : Santé publique.
- économie : Programmes de vaccination, Santé publique.
- Coopération internationale, Humains, Infection par le virus Zika, Maladies négligées, Organisation mondiale de la santé, Pays en voie de développement, Poliomyélite, Programmes de vaccination, Santé mondiale, Secteur privé, Vaccins, Épidémies, Éradication de maladie.
English descriptors
- KwdEn :
- Developing Countries, Disease Eradication, Epidemics (prevention & control), Global Health, Humans, Immunization Programs (economics), Immunization Programs (statistics & numerical data), International Cooperation, Neglected Diseases (prevention & control), Poliomyelitis (prevention & control), Private Sector, Public Health (economics), Public Health (legislation & jurisprudence), Vaccination Coverage, Vaccines, World Health Organization, Zika Virus Infection (prevention & control).
- MESH :
- chemical : Vaccines.
- economics : Immunization Programs, Public Health.
- legislation & jurisprudence : Public Health.
- prevention & control : Epidemics, Neglected Diseases, Poliomyelitis, Zika Virus Infection.
- statistics & numerical data : Immunization Programs.
- Developing Countries, Disease Eradication, Global Health, Humans, International Cooperation, Private Sector, Vaccination Coverage, World Health Organization.
Abstract
This report covers the topics of pandemics, epidemics and partnerships, including regulatory convergence initiatives, new technologies and novel vaccines, discussed by leading public and private sector stakeholders at the 18th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers' Network (DCVMN). Contributions of Gavi and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical development of innovative vaccines for future MERS, Zika or other outbreak response. Priorities for vaccine stockpiling, to assure readiness during emergencies and to prevent outbreaks due to re-emerging diseases such as yellow fever, cholera and poliomyelitis, were outlined. The role of partnerships in improving global vaccine access, procurement and immunization coverage, and shared concerns were reviewed. The World Health Organization (WHO) and other international collaborating partners provided updates on the Product, Price and Procurement database, the prequalification of vaccines, the control of neglected tropical diseases, particularly the new rabies elimination initiative, and regulatory convergence proposals to accelerate vaccine registration in developing countries. Updates on supply chain innovations and novel vaccine platforms were presented. The discussions enabled members and partners to reflect on efficiency of research & development, supply chain tools and trends in packaging technologies improving delivery of existing vaccines, and allowing a deeper understanding of the current public-health objectives, industry financing, and global policies, required to ensure optimal investments, alignment and stability of vaccine supply in developing countries.
DOI: 10.1016/j.vaccine.2018.05.035
PubMed: 29789241
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000894
Links to Exploration step
pubmed:29789241Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccines, inspiring innovation in health.</title><author><name sortKey="Pagliusi, Sonia" sort="Pagliusi, Sonia" uniqKey="Pagliusi S" first="Sonia" last="Pagliusi">Sonia Pagliusi</name><affiliation wicri:level="1"><nlm:affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn.net.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>DCVMN International, Route de Crassier 7, 1262 Nyon</wicri:regionArea></affiliation></author><author><name sortKey="Dennehy, Maureen" sort="Dennehy, Maureen" uniqKey="Dennehy M" first="Maureen" last="Dennehy">Maureen Dennehy</name><affiliation wicri:level="1"><nlm:affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: maureen@qast.co.za.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>DCVMN International, Route de Crassier 7, 1262 Nyon</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do, South Korea. Electronic address: ebolakim@sk.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Vaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29789241</idno><idno type="pmid">29789241</idno><idno type="doi">10.1016/j.vaccine.2018.05.035</idno><idno type="wicri:Area/PubMed/Corpus">000894</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000894</idno><idno type="wicri:Area/PubMed/Curation">000894</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000894</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccines, inspiring innovation in health.</title><author><name sortKey="Pagliusi, Sonia" sort="Pagliusi, Sonia" uniqKey="Pagliusi S" first="Sonia" last="Pagliusi">Sonia Pagliusi</name><affiliation wicri:level="1"><nlm:affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn.net.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>DCVMN International, Route de Crassier 7, 1262 Nyon</wicri:regionArea></affiliation></author><author><name sortKey="Dennehy, Maureen" sort="Dennehy, Maureen" uniqKey="Dennehy M" first="Maureen" last="Dennehy">Maureen Dennehy</name><affiliation wicri:level="1"><nlm:affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: maureen@qast.co.za.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>DCVMN International, Route de Crassier 7, 1262 Nyon</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Hun" sort="Kim, Hun" uniqKey="Kim H" first="Hun" last="Kim">Hun Kim</name><affiliation wicri:level="1"><nlm:affiliation>Vaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do, South Korea. Electronic address: ebolakim@sk.com.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Vaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do</wicri:regionArea></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Developing Countries</term><term>Disease Eradication</term><term>Epidemics (prevention & control)</term><term>Global Health</term><term>Humans</term><term>Immunization Programs (economics)</term><term>Immunization Programs (statistics & numerical data)</term><term>International Cooperation</term><term>Neglected Diseases (prevention & control)</term><term>Poliomyelitis (prevention & control)</term><term>Private Sector</term><term>Public Health (economics)</term><term>Public Health (legislation & jurisprudence)</term><term>Vaccination Coverage</term><term>Vaccines</term><term>World Health Organization</term><term>Zika Virus Infection (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Coopération internationale</term><term>Humains</term><term>Infection par le virus Zika ()</term><term>Maladies négligées ()</term><term>Organisation mondiale de la santé</term><term>Pays en voie de développement</term><term>Poliomyélite ()</term><term>Programmes de vaccination ()</term><term>Programmes de vaccination (économie)</term><term>Santé mondiale</term><term>Santé publique (législation et jurisprudence)</term><term>Santé publique (économie)</term><term>Secteur privé</term><term>Vaccins</term><term>Épidémies ()</term><term>Éradication de maladie</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Vaccines</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Immunization Programs</term><term>Public Health</term></keywords><keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en"><term>Public Health</term></keywords><keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr"><term>Santé publique</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Epidemics</term><term>Neglected Diseases</term><term>Poliomyelitis</term><term>Zika Virus Infection</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Immunization Programs</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Programmes de vaccination</term><term>Santé publique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Developing Countries</term><term>Disease Eradication</term><term>Global Health</term><term>Humans</term><term>International Cooperation</term><term>Private Sector</term><term>Vaccination Coverage</term><term>World Health Organization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coopération internationale</term><term>Humains</term><term>Infection par le virus Zika</term><term>Maladies négligées</term><term>Organisation mondiale de la santé</term><term>Pays en voie de développement</term><term>Poliomyélite</term><term>Programmes de vaccination</term><term>Santé mondiale</term><term>Secteur privé</term><term>Vaccins</term><term>Épidémies</term><term>Éradication de maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This report covers the topics of pandemics, epidemics and partnerships, including regulatory convergence initiatives, new technologies and novel vaccines, discussed by leading public and private sector stakeholders at the 18th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers' Network (DCVMN). Contributions of Gavi and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical development of innovative vaccines for future MERS, Zika or other outbreak response. Priorities for vaccine stockpiling, to assure readiness during emergencies and to prevent outbreaks due to re-emerging diseases such as yellow fever, cholera and poliomyelitis, were outlined. The role of partnerships in improving global vaccine access, procurement and immunization coverage, and shared concerns were reviewed. The World Health Organization (WHO) and other international collaborating partners provided updates on the Product, Price and Procurement database, the prequalification of vaccines, the control of neglected tropical diseases, particularly the new rabies elimination initiative, and regulatory convergence proposals to accelerate vaccine registration in developing countries. Updates on supply chain innovations and novel vaccine platforms were presented. The discussions enabled members and partners to reflect on efficiency of research & development, supply chain tools and trends in packaging technologies improving delivery of existing vaccines, and allowing a deeper understanding of the current public-health objectives, industry financing, and global policies, required to ensure optimal investments, alignment and stability of vaccine supply in developing countries.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29789241</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>48</Issue><PubDate><Year>2018</Year><Month>11</Month><Day>19</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Vaccines, inspiring innovation in health.</ArticleTitle><Pagination><MedlinePgn>7430-7437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(18)30655-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2018.05.035</ELocationID><Abstract><AbstractText>This report covers the topics of pandemics, epidemics and partnerships, including regulatory convergence initiatives, new technologies and novel vaccines, discussed by leading public and private sector stakeholders at the 18th Annual General Meeting (AGM) of the Developing Countries Vaccine Manufacturers' Network (DCVMN). Contributions of Gavi and the vaccine industry from emerging countries to the growing global vaccine market, by improving the supply base from manufacturers in developing countries and contributing to 58% of doses, were highlighted. The Coalition for Epidemic Preparedness Innovations (CEPI), the International Vaccine Institute (IVI) and others reported on new strategies to ensure speedy progress in preclinical and clinical development of innovative vaccines for future MERS, Zika or other outbreak response. Priorities for vaccine stockpiling, to assure readiness during emergencies and to prevent outbreaks due to re-emerging diseases such as yellow fever, cholera and poliomyelitis, were outlined. The role of partnerships in improving global vaccine access, procurement and immunization coverage, and shared concerns were reviewed. The World Health Organization (WHO) and other international collaborating partners provided updates on the Product, Price and Procurement database, the prequalification of vaccines, the control of neglected tropical diseases, particularly the new rabies elimination initiative, and regulatory convergence proposals to accelerate vaccine registration in developing countries. Updates on supply chain innovations and novel vaccine platforms were presented. The discussions enabled members and partners to reflect on efficiency of research & development, supply chain tools and trends in packaging technologies improving delivery of existing vaccines, and allowing a deeper understanding of the current public-health objectives, industry financing, and global policies, required to ensure optimal investments, alignment and stability of vaccine supply in developing countries.</AbstractText><CopyrightInformation>Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pagliusi</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennehy</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: maureen@qast.co.za.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Vaccine Business Group, SK Chemicals, SK Chemicals Complex, 332, Pangyo-ro, Bundang-gu, Seongnam-si, 13493 Gyeonggi-do, South Korea. Electronic address: ebolakim@sk.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DCVMN AGM Organizing Committee</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003906" MajorTopicYN="Y">Developing Countries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058872" MajorTopicYN="N">Epidemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="Y">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058069" MajorTopicYN="N">Neglected Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017149" MajorTopicYN="N">Private Sector</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000331" MajorTopicYN="N">legislation & jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073887" MajorTopicYN="N">Vaccination Coverage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071243" MajorTopicYN="N">Zika Virus Infection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Developing countries</Keyword><Keyword MajorTopicYN="Y">Epidemic</Keyword><Keyword MajorTopicYN="Y">Procurement</Keyword><Keyword MajorTopicYN="Y">Stockpiling</Keyword><Keyword MajorTopicYN="Y">Technology</Keyword><Keyword MajorTopicYN="Y">Vaccine manufacturing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29789241</ArticleId><ArticleId IdType="pii">S0264-410X(18)30655-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.035</ArticleId><ArticleId IdType="pmc">PMC6238075</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wkly Epidemiol Rec. ;92(16):193-204</Citation><ArticleIdList><ArticleId IdType="pubmed">28429585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2018 Jun 7;36(24):3389-3396</Citation><ArticleIdList><ArticleId IdType="pubmed">29724510</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2016 Sep 3;388(10048):994-1001</Citation><ArticleIdList><ArticleId IdType="pubmed">27402381</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Oct 1;31(42):4714-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23994374</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 May 9;23(25):3232-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15837226</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Microbiol. 2016 Aug;14(8):523-34</Citation><ArticleIdList><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2012 Feb 11;379(9815):547-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22226047</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 Jul 24;35(33):4099-4104</Citation><ArticleIdList><ArticleId IdType="pubmed">28668573</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation><ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2017 Sep 08;66(35):928-932</Citation><ArticleIdList><ArticleId IdType="pubmed">28880856</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2017 Feb 6;24(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">27974397</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Health Aff (Millwood). 2011 Jun;30(6):1021-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21653952</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 May;21(5):741-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25897654</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2006 Sep;13(9):1004-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16960111</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2013 Apr 18;31 Suppl 2:B61-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23598494</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2009 Dec 11;28(2):571-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19833249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2015 Nov 17;33(46):6360-5</Citation><ArticleIdList><ArticleId IdType="pubmed">26348402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2017 Mar 23;376(12):1121-1130</Citation><ArticleIdList><ArticleId IdType="pubmed">28328346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Jul 11;369(2):155-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23841730</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2005 Jun 1;174(11):7446-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15905594</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2017 May 19;35(22):2962-2969</Citation><ArticleIdList><ArticleId IdType="pubmed">28434688</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000894 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000894 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29789241
|texte= Vaccines, inspiring innovation in health.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29789241" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |